Trial Profile
VECODUE A Phase II Trial of Vemurafenib Plus Cobimetinib in Patients Treated With Prior First-line Systemic Immunotherapy for Inoperable Locally Advanced or Metastatic Melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms VECODUE
- 23 Apr 2021 Status changed from recruiting to discontinued.
- 21 Jul 2020 Planned End Date changed from 1 Mar 2020 to 1 Dec 2022.
- 21 Jul 2020 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2021.